Back to search
Verified
Government
Health
Ryplle ID RYP-0642Last checked Oct 28, 2026

Immune Tolerance Network (UM1 Clinical Trial Required)

National Institutes of Health

Funding range
$0 – $22.0M
Application window
Opens: Not listed
Closes: January 29, 2027
Applications Status:Upcoming
Location
National
Apply on funder's site

Source & verification

Original funding source
www.grants.gov
Last checked
October 28, 2026
Last reviewed by Ryplle
Not yet recorded

Source checks may be automated. Review dates reflect a recorded staff review. Confirm current requirements with the funder.

Eligibility at a glance

Listed applicant types
Student, Business, Nonprofit
Geographic eligibility
National
Matching funds
Not specified — check with the funder
Major exclusions
Not specified — check with the funder

Listed types are not a determination of eligibility. The funder’s full requirements take precedence.

Full eligibility requirements

Eligible applicants: City or township governments; Independent school districts; Special district governments; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public housing authorities/Indian housing authorities; Public and State controlled institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Native American tribal governments (Federally recognized); County governments.

About this grant

The purpose of this notice of funding opportunity (NOFO) is to support applications to continue the Immune Tolerance Network (ITN). The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies.

Contact information